Fox Rothschild advised HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, in its management-led majority stake acquisition by a syndicate of globally recognized private and public investors including K5 Global, Bezos Expeditions and Wellington Management, and other new and existing investors.

The transaction values HistoSonics at approximately $2.25 billion and positions the company for accelerated growth of its breakthrough Edison System, which uses non-invasive focused ultrasound energy to destroy targeted tissue and tumors, through new clinical indications and global markets.

Please refer to HistoSonics’ press release for additional information. HistoSonics and this deal were highlighted in the Wall Street Journal.

Fox attorneys Brett Hanson and Eric Bielefeldt led the Fox team advising HistoSonics. Fox has served as corporate counsel to HistoSonics since 2017.